# References — EAC manuscript

All DOIs resolved and checked against CrossRef (no retraction flags).

1. Coleman et al. (2018). *The Epidemiology of Esophageal Adenocarcinoma*. https://doi.org/10.1053/j.gastro.2017.07.046

2. Spechler & Souza (2014). *Barrett's Esophagus*. https://doi.org/10.1056/nejmra1314704

3. TCGA Research Network (2017). *Integrated genomic characterization of oesophageal carcinoma*. https://doi.org/10.1038/nature20805

4. Bang et al. (2010). *Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)*. https://doi.org/10.1016/s0140-6736(10)61121-x

5. Kelly et al. (2021). *Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)*. https://doi.org/10.1056/nejmoa2032125

6. Fuchs et al. (2014). *Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD)*. https://doi.org/10.1016/s0140-6736(13)61719-5

7. Shitara et al. (2023). *Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT)*. https://doi.org/10.1016/s0140-6736(23)00620-7

8. Klempner et al. (2024). *DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)*. https://doi.org/10.1200/jco.24.00410